Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of oxytocin-treated children with Prader-Willi syndrome from OTBB3 compared with untreated cohort
2020-006161-11Phase 3Active
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of oxytocin in Prader-Willi syndrome (PWS) (2 cohorts), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Long-term safety (AEs and SAEs). Started Apr 2021; status: active.
02
Drugs
oxytocin
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on 2020-006161-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006161-11.